Crispr Therapeutics (CRSP) Stock

CRISPR Therapeutics AG (CRSP) is a biotechnology company developing gene‑editing therapies based on the CRISPR/Cas9 platform. The firm focuses on both ex vivo and in vivo programmes, with clinical-stage candidates targeting genetic blood disorders, certain cancers and other rare diseases. CRISPR’s progress depends on successful clinical trials, regulatory approvals and manufacturing scale-up; its collaboration strategy (notably with large partners) aims to de‑risk development and broaden commercial reach. As of the provided market data the company has a market capitalisation of about $6.58 billion. Investors should note the typical biotech profile: meaningful upside if trials succeed, but significant clinical, regulatory and execution risk if they do not. Research and development spending is a major cash use and share prices can be volatile around trial readouts. This summary is educational only and not personal investment advice; consider suitability, diversification and your risk tolerance before acting.